Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Specimen Handling 449Magnetic Resonance Spectroscopy 344pembrolizumab 296Biopsy 247Carboplatin 235Cisplatin 198Cyclophosphamide 190Paclitaxel 167Nivolumab 158Gemcitabine 154Bevacizumab 125Radiotherapy 122Dexamethasone 115fludarabine 102Pemetrexed 102Fluorouracil 96Doxorubicin 92venetoclax 91durvalumab 91Radiation 91Docetaxel 91atezolizumab 90Oxaliplatin 89Rituximab 88Leucovorin 82Capecitabine 78Prednisone 77Lenalidomide 71Etoposide 69X-Rays 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uric Acid × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡